Last reviewed · How we verify
Psoriasis
Approved treatments
- Allantol
- Allomaleic Acid
- Stelara · Biocon Biologics UK Ltd
- In open-label phase: treatment with tofacitinib · Pfizer
- Tegison
- Solu-Cortef · Pfizer
- Cortifoam · Pfizer
- Cortone
- ammonia
- Celestone Soluspan
- Decadron · Generic (originally Merck)
- ANTHRALIN
- Stelara · Johnson & Johnson
Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation. - prednison · Wen Zhang
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Veradex-E · ABBE Laboratories, Inc.
- Cortef · Generic (originally Merck/Upjohn)
- Rodinolone
- Deltasone · Generic (originally Schering)
- Infliximab [infliximab biosimilar 3] · Pfizer
Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions. - Skyrizi · AbbVie
Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response. - Betametasone
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
- Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
- Methylprednisolon · Leiden University Medical Center
Pipeline
- CROMOLYN SODIUM — Phase 2
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: